Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab PET/CT arterial inflammation study in familial hypercholesterolemia
NL-OMON43194Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of alirocumab in familial hypercholesterolemia (FH) and atherosclerosis, sponsored by Amsterdam University Medical Center. Primary endpoint: Arterial wall inflammation by 18F-FDG PET/CT. Planned start Sep 2016; status: withdrawn.
02
Drugs
alirocumab
03
Conditions
familial hypercholesterolemia (FH)atherosclerosis
Beyond the preview
Go deeper on NL-OMON43194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43194.